
Hawaii’s official report shows deaths after taking prescribed aid-in-dying drugs rose 55% in 2025, the program’s highest annual total so far.
Story Highlights
- State report recorded 59 deaths after ingestion in 2025, up from 38 in 2024.
- Ninety-three people received prescriptions; 74 eligible patients were known to have died.
- Cumulative deaths after ingestion reached 254 since the law took effect in 2019.
- Officials and watchdogs cite gaps in follow-up data, which may undercount outcomes.
Official Numbers From Hawaii’s Aid-in-Dying Program
Hawaii’s Department of Health annual report on the Our Care, Our Choice Act documented 59 deaths in 2025 following ingestion of prescribed medication, compared with 38 in 2024. That 21-case increase equals about 55.3 percent. The Garden Island reported that 59 is the highest yearly total since the law began in 2019. The same reporting said 93 eligible patients received prescriptions in 2025, and 74 eligible patients were known to have died that year. These figures anchor the current debate.
The report’s language, as summarized by multiple outlets, tracks three related counts: prescriptions issued, known deaths among eligible patients, and deaths after ingestion. The 59 ingestion deaths represent confirmed medication use. The 93 prescriptions show access and demand. The gap between the two reflects the reality that not every prescription leads to ingestion, and not every outcome is reported. The cumulative total of ingestion deaths reached 254 through 2025, according to local coverage of the state report.
What The Counts Do—and Do Not—Tell Us
The jump in documented ingestion deaths is clear. The reasons for the increase are not. The available coverage does not identify whether the rise comes from more prescriptions, higher use of prescriptions, better reporting, or changes in who qualifies. News accounts note that health officials acknowledge incomplete follow-up data. That means the 59 figure measures recorded ingestion deaths and may not capture every outcome tied to a prescription. The core facts stand, but the causes behind them are not established in the public summaries.
These limits are not unique to Hawaii. Research on assisted-dying programs shows data often rely on self-reports from clinicians and pharmacists, with uneven detail and auditing. Differences in definitions, eligibility rules, and reporting systems make it hard to compare across places or track deeper drivers over time. Academic assessments urge stronger monitoring and clearer, standardized reporting to fill gaps and support better oversight and public understanding. Those themes echo here, where headline numbers outpace available explanations.
Why This Matters Across The Political Spectrum
Families on islands face hard end-of-life choices, rising costs, and limited specialty care. Supporters see the law as a guarded option to ease suffering. Critics worry about pressure on the sick, the elderly, and people with fewer resources. Both sides want a system that is careful, transparent, and accountable. Incomplete follow-up fuels concern that officials count what gets reported, not everything that happens, which can erode confidence in any program that touches life and death.
Hawaii sees 55% increase in assisted suicide deaths https://t.co/ImzpWCKO2c pic.twitter.com/bDzTMe2Pes
— Live Action News (@LiveActionNews) November 16, 2026
Small programs can show big percentage swings, but even small changes matter when each case is a person and a family. Clearer data could answer key questions most readers share: Who gets prescriptions, who ingests, what safeguards worked, and where did they fail? Lawmakers, health leaders, and patient advocates could agree on one step now—publish fuller, timely, and audited records that link prescriptions, outcomes, and death-certificate practices. Good data will not settle every moral debate, but it will support wiser choices.
What To Watch Next in Hawaii
Watch for the health department to release the full 2025 report with tables, definitions, and methods. Look for any legislative hearings on program oversight, reporting rules, and provider participation. Track whether the state improves follow-up so prescription, ingestion, and death data align more closely. If those steps happen, future reports could show not only how many people used the law, but also why, under what safeguards, and with what results for patients and families.
Sources:
lifesitenews.com, thegardenisland.com, ontario.ca, thelancet.com
© nationalusnews.com 2026. All rights reserved.














